^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Waldenstrom Macroglobulinemia

    Related cancers:
    Apply
    Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    05/20/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    BCL2 • BCL6 • CD4
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous
    Ibrutinib + Venetoclax in Untreated WM (NCT04273139)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/09/2020
    Primary completion :
    06/06/2022
    Completion :
    02/01/2028
    BCL2 • MYD88
    |
    MYD88 mutation
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia (NCT03506373)
    Phase 2
    Mayo Clinic
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    08/14/2018
    Primary completion :
    02/06/2023
    Completion :
    03/11/2026
    SDC1
    |
    Imbruvica (ibrutinib) • Ninlaro (ixazomib)
    Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation (NCI-2017-01311) (NCT03246906)
    Phase 2
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    09/11/2017
    Primary completion :
    05/03/2025
    Completion :
    05/03/2025
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous
    Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (MT2015-29) (NCT03314974)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    03/30/2018
    Primary completion :
    06/10/2025
    Completion :
    06/10/2026
    NPM1 • KMT2A • IKZF1 • CEBPA
    |
    NPM1 mutation • MLL rearrangement
    |
    cyclophosphamide
    Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia (BGB-3111-402) (NCT05640102)
    Phase N/A
    BeiGene
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    03/03/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2027
    MYD88
    |
    MYD88 mutation • MYD88 L265P • MYD88 wild-type
    |
    Brukinsa (zanubrutinib)
    Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma (NCI-2018-01880) (NCT03884998)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    02/26/2019
    Primary completion :
    07/16/2025
    Completion :
    07/16/2025
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Aliqopa (copanlisib)
    Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (NCI-2018-00315) (NCT03479268)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/22/2018
    Primary completion :
    06/22/2025
    Completion :
    06/22/2025
    CCND1 • FCER2
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)
    Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström's Macroglobulinemia (BGB-11417-203) (NCT05952037)
    Phase 2
    BeiGene
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    09/28/2023
    Primary completion :
    11/01/2027
    Completion :
    09/01/2028
    BCL2
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma (C1763102) (NCT05602363)
    Phase 1
    Carna Biosciences, Inc.
    Recruiting
    Last update posted :
    11/01/2024
    Initiation :
    08/01/2023
    Primary completion :
    09/01/2027
    Completion :
    09/01/2027
    PLCG2
    |
    PLCG2 mutation
    |
    docirbrutinib (AS-1763)
    CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma (NCT04578600)
    Phase 1
    Joseph Tuscano
    Active, not recruiting
    Last update posted :
    09/19/2024
    Initiation :
    10/23/2020
    Primary completion :
    12/01/2024
    Completion :
    07/01/2025
    CD20 • CD4
    |
    lenalidomide • Gazyva (obinutuzumab) • Onureg (azacitidine oral)
    19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers (NCT04464200)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    08/23/2024
    Initiation :
    07/06/2020
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    CD20
    A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729)
    Phase 1/2
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    06/12/2024
    Initiation :
    12/05/2017
    Primary completion :
    03/29/2024
    Completion :
    11/16/2037
    BCL2
    |
    CD20 expression
    |
    cyclophosphamide • fludarabine IV • MB-106
    Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) (BELLWAVE-003) (NCT04728893)
    Phase 2
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    04/05/2021
    Primary completion :
    03/19/2027
    Completion :
    03/19/2027
    TP53 • CCND1 • CD4
    |
    TP53 mutation • Chr t(11;14) • CCND1 overexpression
    |
    nemtabrutinib (MK-1026)
    Study of SGR-1505 in Mature B-Cell Neoplasms (SGR-1505-101) (NCT05544019)
    Phase 1
    Schrödinger, Inc.
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    04/10/2023
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    BCL2
    |
    SGR-1505
    A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies (NX-5948-301) (NCT05131022)
    Phase 1
    Nurix Therapeutics, Inc.
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/13/2022
    Primary completion :
    12/01/2025
    Completion :
    01/01/2027
    BCL2 • BCL6
    |
    NX-5948
    Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCI-2017-01069) (NCT03192397)
    Phase 1/2
    Roswell Park Cancer Institute
    Active, not recruiting
    Last update posted :
    05/29/2024
    Initiation :
    08/09/2017
    Primary completion :
    08/21/2023
    Completion :
    05/21/2027
    HLA-DRB1
    |
    cyclophosphamide • sirolimus • melphalan • fludarabine IV • captisol-enabled melphalan • cyclophosphamide intravenous
    Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633)
    Phase 2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    01/25/2021
    Primary completion :
    12/31/2024
    Completion :
    12/31/2026
    HLA-DRB1
    |
    cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • Neupogen (filgrastim) • cyclophosphamide intravenous
    Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (NCT04263480)
    Phase 2
    Christian Buske
    Recruiting
    Last update posted :
    05/14/2024
    Initiation :
    02/18/2021
    Primary completion :
    02/01/2028
    Completion :
    02/01/2028
    CD20 • MYD88 • CXCR4
    |
    CD20 positive
    |
    Imbruvica (ibrutinib) • carfilzomib
    Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia (NCT03620903)
    Phase 2
    Christian Buske
    Active, not recruiting
    Last update posted :
    05/13/2024
    Initiation :
    09/11/2019
    Primary completion :
    11/14/2022
    Completion :
    09/01/2029
    CD20 • CD5 • MME • FCER2
    |
    CD5 positive
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bortezomib
    Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia (VIWA-1) (NCT05099471)
    Phase 2
    University of Ulm
    Not yet recruiting
    Last update posted :
    05/13/2024
    Initiation :
    09/01/2024
    Primary completion :
    10/01/2027
    Completion :
    10/01/2032
    MYD88 • CXCR4
    |
    CXCR4 mutation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • cyclophosphamide • cyclophosphamide intravenous
    Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia (NCT01788020)
    Phase 3
    University of Ulm
    Completed
    Last update posted :
    05/13/2024
    Initiation :
    11/01/2013
    Primary completion :
    11/01/2018
    Completion :
    04/01/2024
    CD20 • CD5 • MME • FCER2
    |
    CD20 positive • CD5 positive
    |
    Rituxan (rituximab) • bortezomib • cyclophosphamide • dexamethasone • cyclophosphamide intravenous
    Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies (NCT04191187)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    05/03/2024
    Initiation :
    12/06/2019
    Primary completion :
    02/11/2024
    Completion :
    02/01/2025
    HLA-DRB1 • HLA-B • HLA-C
    |
    melphalan • fludarabine IV
    ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy (NCT05065554)
    Phase 2
    Shayna Sarosiek, MD
    Recruiting
    Last update posted :
    04/17/2024
    Initiation :
    11/16/2021
    Primary completion :
    12/01/2026
    Completion :
    10/01/2028
    CD20 • CD22 • IL2RA • CD5 • SDC1 • CD27 • MME • ITGAE • FCER2
    |
    Rituxan (rituximab) • Calquence (acalabrutinib)
    Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (NCT03674411)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Active, not recruiting
    Last update posted :
    04/10/2024
    Initiation :
    01/02/2019
    Primary completion :
    06/23/2020
    Completion :
    06/28/2024
    FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA
    |
    FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type
    |
    cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)
    Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia (NCT05734495)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    04/09/2024
    Initiation :
    05/02/2023
    Primary completion :
    01/25/2029
    Completion :
    01/25/2033
    BCL2 • MYD88
    |
    MYD88 wild-type
    |
    Venclexta (venetoclax) • Jaypirca (pirtobrutinib)
    AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas (NCT06340737)
    Phase 1
    Stanford University
    Recruiting
    Last update posted :
    04/03/2024
    Initiation :
    03/29/2024
    Primary completion :
    04/01/2031
    Completion :
    04/01/2031
    CD22
    Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015)
    Phase 1
    City of Hope Medical Center
    Completed
    Last update posted :
    04/02/2024
    Initiation :
    10/29/2012
    Primary completion :
    02/02/2024
    Completion :
    02/02/2024
    HLA-DRB1
    |
    PD-1 expression
    |
    Promune (agatolimod)
    A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (BELLWAVE-001) (NCT03162536)
    Phase 1/2
    ArQule, Inc., a subsidiary of Merck Sharp & Doh...
    Active, not recruiting
    Last update posted :
    03/08/2024
    Initiation :
    06/26/2017
    Primary completion :
    09/12/2025
    Completion :
    09/12/2025
    BCL2 • BCL6
    |
    BTK mutation • BCL6 translocation • BTK C481
    |
    nemtabrutinib (MK-1026)
    Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (NCT00719888)
    Phase 2
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    01/05/2024
    Initiation :
    11/18/2005
    Primary completion :
    12/22/2023
    Completion :
    12/22/2024
    HLA-DRB1 • HLA-B
    |
    cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion • cyclophosphamide intravenous
    Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma (NCT01815749)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/04/2024
    Initiation :
    10/08/2013
    Primary completion :
    01/09/2018
    Completion :
    09/27/2024
    EGFR • CD34
    Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas (NCT02332980)
    Phase 2
    Mayo Clinic
    Completed
    Last update posted :
    01/03/2024
    Initiation :
    02/19/2015
    Primary completion :
    08/10/2021
    Completion :
    01/04/2022
    CD20 • PD-1 • CCND1 • IGH • PD-L2 • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • Zydelig (idelalisib)
    Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL (MB106-CD20-001) (NCT05360238)
    Phase 1/2
    Mustang Bio
    Recruiting
    Last update posted :
    12/20/2023
    Initiation :
    05/24/2022
    Primary completion :
    09/01/2026
    Completion :
    09/01/2026
    BCL2 • CD20 • BCL6
    |
    CD19 positive • CD20 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    MB-106
    Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia (NCT05281809)
    Phase 2
    John Lister
    Recruiting
    Last update posted :
    12/11/2023
    Initiation :
    04/19/2022
    Primary completion :
    08/05/2037
    Completion :
    12/01/2037
    CD19
    |
    CD19 expression
    Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies (NCT01523223)
    Phase 1
    Robert Lowsky
    Completed
    Last update posted :
    11/22/2023
    Initiation :
    01/01/2012
    Primary completion :
    09/01/2016
    Completion :
    10/01/2016
    CD8
    A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies (NX-2127-001) (NCT04830137)
    Phase 1
    Nurix Therapeutics, Inc.
    Active, not recruiting
    Last update posted :
    11/07/2023
    Initiation :
    05/05/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    TP53 • CD4
    |
    TP53 mutation • BTK C481
    |
    zelebrudomide (NX-2127)
    Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NCT01962636)
    Phase N/A
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    11/03/2023
    Initiation :
    12/01/2016
    Primary completion :
    10/01/2024
    Completion :
    10/01/2025
    KMT2A • IKZF1
    |
    MLL rearrangement • MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • cyclosporin A microemulsion • cyclophosphamide intravenous
    Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer (NCT05172700)
    Phase N/A
    Loxo Oncology, Inc.
    Available
    Last update posted :
    10/20/2023
    BCL2
    |
    Jaypirca (pirtobrutinib)
    Allo HSCT Using RIC for Hematological Diseases (NCT02661035)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Completed
    Last update posted :
    09/21/2023
    Initiation :
    03/09/2017
    Primary completion :
    04/17/2023
    Completion :
    05/29/2023
    FLT3 • KMT2A • IKZF1 • HLA-DRB1 • HLA-B • HLA-C
    |
    MLL rearrangement • MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • methylprednisolone sodium succinate
    Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma (NCT03010358)
    Phase 1/2
    Alexey Danilov, MD
    Completed
    Last update posted :
    08/08/2023
    Initiation :
    07/17/2017
    Primary completion :
    04/29/2021
    Completion :
    04/29/2021
    CCND1 • FCER2
    |
    Chr t(11;14) • CCND1 overexpression
    |
    Gazyva (obinutuzumab) • entospletinib (GS-9973)